Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 9/20 | 0.56 |
| ▸ | MC5R | P33032 | 9/20 | 0.56 |
| ▸ | MC3R | P41968 | 9/20 | 0.56 |
| ▸ | MC1R | Q01726 | 9/20 | 0.56 |
| ▸ | CTSG | P08311 | 2/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 2/20 | 0.51 |
| ▸ | TSLP | Q969D9 | 3/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | GRB7 | Q14451 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13486968 | 0.97 | MC4R (0.57) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL12918062 | 0.94 | MC4R (0.58) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL12482122 | 0.94 | MC4R (0.57) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL10327237 | 0.93 | MC4R (0.57) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL9908285 | 0.93 | MC4R (0.54) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL13485740 | 0.92 | MC4R (0.58) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL12918029 | 0.88 | MC4R (0.57) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL12307752 | 0.88 | MC4R (0.53) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL9909398 | 0.88 | MC4R (0.59) | MC4RMC5RMC3RMC1RCTSG | |
| SCHEMBL14004123 | 0.88 | TSLP (0.57) | MC4RMC5RMC3RMC1RCTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216548-B2 | Radiofluorination methods | GE HEALTHCARE AS (NO) | 2012-07-10 | — | — | US | disclosed |
| US-8216548-B2 | Radiofluorination methods | GE HEALTHCARE AS (NO) | 2012-07-10 | — | — | US | disclosed |
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| US-7972588-B2 | Radiolabelling methods | HAMMERSMITH IMANET LIMITED (GB) | 2011-07-05 | — | — | US | disclosed |
| US-20100178242-A1 | LABELLING METHODS | GE HEALTHCARE LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| US-20100069609-A1 | CHEMICAL METHODS AND APPARATUS | ARSTAD ERIK | 2010-03-18 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| US-20100034740-A1 | RADIOFLUORINATION METHODS | GE HEALTHCARE AS (NO) | 2010-02-11 | — | — | US | disclosed |
| US-20100034740-A1 | RADIOFLUORINATION METHODS | GE HEALTHCARE AS (NO) | 2010-02-11 | — | — | US | disclosed |
| US-20090311177-A1 | Radiolabelling Methods | GE HEALTHCARE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178242-A1 | LABELLING METHODS | FURIN, FGF23, FGF2 | MC4R 1641/4885MC5R 2483/4885MC3R 2782/4885 |
| US-20100034740-A1 | RADIOFLUORINATION METHODS | CYP2F1, CYP4F2, CYP4F3 | MC4R 2530/4885MC5R 1392/4885MC3R 2134/4885 |
| US-20090311177-A1 | Radiolabelling Methods | CTSV, NGLY1, MAN2B1 | MC4R 3092/4885MC5R 3371/4885MC3R 1836/4885 |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | DOHH, VGF, HNRNPH3 | MC4R 3215/4885MC5R 2746/4885MC3R 2694/4885 |
| US-20100069609-A1 | CHEMICAL METHODS AND APPARATUS | C9, KDR, TIE1 | MC4R 1907/4885MC5R 2075/4885MC3R 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.